Complement C1 inhibitor protein (Shire ViroPharma)

N/A

Report date: 2022/02/11 11:14:49

Base Information

Drug NameComplement C1 inhibitor protein (Shire ViroPharma)
Drug Alias NameC1 Esterase Inhibitor (human)CetorCinryzeC1 INH-nfC1-INH +[6] 
ClassificationBiologics > Blood components
Mechanisms of ActionSerine protease inhibitorsComplement C1s inhibitorsComplement C1r inhibitors
TargetsSerine proteaseComplement C1sComplement C1r
Therapy Area/IndicationsRejection of organ transplantationGraft RejectionAngioedemas, Hereditary +[4] 
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2008/10/10
Country/TerritoryBelgiumUnited StatesRomania +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanquin Plasma Products Bv
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Manufacturing Austria AgLeiden University Medical Center
Inactive CompaniesCsl BehringShire
Active IndicationsAngioedemas, HereditaryBrain Injuries, Traumatic
Inactive IndicationsRejection of organ transplantationGraft Rejection

Other Information

ATC CodeB06AC01
Related LinksN/A